Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Nucynta CR | Tapentadol | Pain, moderate to moderately severe | Do not list | Complete | ||
Nurtec ODT | rimegepant | Migraine, prevention | Withdrawn | |||
NuvaRing | Etonogestrel/ethinyl estradiol | Contraceptive, ring | List with clinical criteria and/or conditions | Complete | ||
Ocaliva | Obeticholic Acid | Primary Biliary Cholangitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Ocrevus | ocrelizumab | Primary progressive multiple sclerosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Ocrevus | ocrelizumab | multiple sclerosis, relapsing | Reimburse with clinical criteria and/or conditions | Complete | ||
Odefsey | emtricitabine/rilpivirine/ tenofovir alafenamide | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
Odomzo | Sonidegib | Basal Cell Carcinoma | Do not reimburse | Complete | ||
Ofev | nintedanib | chronic fibrosing interstitial lung diseases | Reimburse with clinical criteria and/or conditions | Complete | ||
Ofev | Nintedanib | Idiopathic pulmonary fibrosis | List with clinical criteria and/or conditions | Complete |